GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.…
Latest News In AI Chips - GridAI Expands Energy Capabilities With Pronghorn Acquisition
GridAI Technologies (NASDAQ: GRDX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 3.160 USD on 20 November 2026, down 19.0% over 52 weeks. Its 52-week range is 1.870 USD to 6.850 USD: the price is 53.9% below the high and 69.0% above the low.
Its market capitalisation is 32.44M USD.
GridAI Technologies reports return on equity of -27.0% and an operating margin of 0.0%.
Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.